Full Press Release Details
SETTLEMENT AND RELEASE OF CLAIMS nmus_ex101.htm EXHIBIT 10.1
SKYE
SETTLEMENT AND RELEASE OF CLAIMS nmus_ex101.htm EXHIBIT 10.1
Key Takeaway: SETTLEMENT AND RELEASE OF CLAIMS nmus_ex101.htm EXHIBIT 10.1
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+84%
120-day peak, hindsight
Typical move
24.3%
average across 4 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
Nimacimab
Phase 2 · Obesity